Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells - PubMed
. 2015 Mar;46(3):1405-11.
doi: 10.3892/ijo.2014.2808. Epub 2014 Dec 23.
Affiliations
- PMID: 25544427
- DOI: 10.3892/ijo.2014.2808
Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
Young-Ah Suh et al. Int J Oncol. 2015 Mar.
Abstract
Ovarian cancer is the number one cause of death from gynaecological malignancy. Platinum-based and taxol-based chemotherapy has been used as a standard therapy, but intrinsic and acquired resistance to chemotherapy is a major obstacle to treat the disease. In the present study, we found that in the chemoresistant ovarian cancer SKOV3/TR cells, interleukin-6 (IL-6), IL-6 receptor and signal transducers and activators of transcription 3 (STAT3) expression as well as STAT3 phosphorylation were upregulated compared to those in parental cells. Silencing of IL-6 using IL-6 siRNA was found to suppress IL-6 production, STAT3 and phosphoSTAT3 levels, which eventually reduced proliferation and clonogenicity of taxol-resistant SKOV3/TR cells. In addition, stattic, a STAT3 inhibitor, was found to result in decrease of cell viability and clonogenicity of these cells, indicating that the elevated IL-6 and STAT3, phosphoSTAT3 levels are associated with the development of taxol resistance. Next, we found anti-proliferative effect of apigenin on both SKOV3 and SKOV3/TR cells. RT-PCR and western blot results showed that apigenin significantly reduced the expression of Axl and Tyro3 receptor tyrosine kinases (RTKs) at mRNA and protein level, which account for its cytotoxic activity. We further found that apigenin decreased Akt phosphorylation and the level of B-cell lymphoma-extra large (Bcl-xl or BCL2-like 1 isoform 1), an inhibitor of apoptosis. On the contrary to these results, apigenin had no effect on IL-6 production, STAT3 and phosphoSTAT3 protein levels, suggesting that apigenin exerts its anti-proliferative activity via downregulation of Axl and Tyro3 expression, Akt phosphorylation and Bcl-xl expression, but not modulation of IL-6/STAT3 axis. Taken together, our data suggest that inhibition of IL-6/STAT3 signaling pathway and downregulation of Axl and Tyro3 RTKs expression might be a therapeutic strategy to overcome taxol resistance in ovarian cancer cells.
Similar articles
-
Lee C. Lee C. Mol Med Rep. 2015 Jul;12(1):1485-92. doi: 10.3892/mmr.2015.3542. Epub 2015 Mar 24. Mol Med Rep. 2015. PMID: 25815442
-
Kim NY, Lee HY, Lee C. Kim NY, et al. Int J Oncol. 2015 Jul;47(1):353-60. doi: 10.3892/ijo.2015.3004. Epub 2015 May 12. Int J Oncol. 2015. PMID: 25975389
-
[Effects of siltuximab on the interleukin-6/Stat3 signaling pathway in ovarian cancer].
Guo YQ, Lu P, Duan ZF, Zhang Z. Guo YQ, et al. Zhonghua Fu Chan Ke Za Zhi. 2010 Nov;45(11):854-9. Zhonghua Fu Chan Ke Za Zhi. 2010. PMID: 21211286 Chinese.
-
Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells.
Corno C, Gatti L, Lanzi C, Zaffaroni N, Colombo D, Perego P. Corno C, et al. Curr Med Chem. 2016;23(15):1496-512. doi: 10.2174/0929867323666160405112954. Curr Med Chem. 2016. PMID: 27048336 Review.
-
Accelerating AXL targeting for TNBC therapy.
Khera L, Lev S. Khera L, et al. Int J Biochem Cell Biol. 2021 Oct;139:106057. doi: 10.1016/j.biocel.2021.106057. Epub 2021 Aug 14. Int J Biochem Cell Biol. 2021. PMID: 34403827 Review.
Cited by
-
Sirotkin AV, Harrath AH. Sirotkin AV, et al. Biomedicines. 2024 Oct 21;12(10):2405. doi: 10.3390/biomedicines12102405. Biomedicines. 2024. PMID: 39457717 Free PMC article. Review.
-
De Marco M, Falco A, Festa M, Raffone A, Sandullo L, Rosati A, Reppucci F, Cammarota AL, Esposito F, Matassa DS, Pascale M, Salzano F, Martinelli R, Remondelli P, Capunzo M, Mollo A, Zullo F, Travaglino A, Guida M, Marzullo L. De Marco M, et al. Am J Cancer Res. 2020 Aug 1;10(8):2596-2602. eCollection 2020. Am J Cancer Res. 2020. PMID: 32905525 Free PMC article.
-
Flavonoids Regulate Inflammation and Oxidative Stress in Cancer.
Li G, Ding K, Qiao Y, Zhang L, Zheng L, Pan T, Zhang L. Li G, et al. Molecules. 2020 Nov 30;25(23):5628. doi: 10.3390/molecules25235628. Molecules. 2020. PMID: 33265939 Free PMC article. Review.
-
Huang WC, Hung CM, Wei CT, Chen TM, Chien PH, Pan HL, Lin YM, Chen YJ. Huang WC, et al. Oncotarget. 2016 Sep 20;7(38):62352-62363. doi: 10.18632/oncotarget.11471. Oncotarget. 2016. PMID: 27694691 Free PMC article.
-
Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Rendell A, et al. Biomedicines. 2022 Aug 29;10(9):2113. doi: 10.3390/biomedicines10092113. Biomedicines. 2022. PMID: 36140214 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous